{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T11:10:49Z","timestamp":1791544249362,"version":"4.3.4"},"reference-count":27,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2019,3,4]],"date-time":"2019-03-04T00:00:00Z","timestamp":1551657600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.msard.2019.02.027","type":"journal-article","created":{"date-parts":[[2019,2,26]],"date-time":"2019-02-26T11:55:58Z","timestamp":1551182158000},"page":"257-261","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"special_numbering":"C","title":["SFX-01 reduces residual disability after experimental autoimmune encephalomyelitis"],"prefix":"10.1016","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1268-5102","authenticated-orcid":false,"given":"Ian","family":"Galea","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian M","family":"Copple","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David W","family":"Howat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Franklin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.msard.2019.02.027_bib0026","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1016\/j.bbadis.2015.09.018","article-title":"Oxidative stress and its impact on neurons and glia in multiple sclerosis lesions","volume":"1862","author":"Lassmann","year":"2016","journal-title":"Biochim Biophys Acta."},{"key":"10.1016\/j.msard.2019.02.027_bib0027","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1016\/j.expneurol.2015.11.010","article-title":"Oxidative stress in multiple sclerosis: Central and peripheral mode of action","volume":"277","author":"Ohl","year":"2016","journal-title":"Exp Neurol."},{"issue":"7","key":"10.1016\/j.msard.2019.02.027_bib0001","doi-asserted-by":"crossref","first-page":"1914","DOI":"10.1093\/brain\/awr128","article-title":"Oxidative damage in multiple sclerosis lesions.","volume":"134","author":"Haider","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.msard.2019.02.027_bib0002","series-title":"Advances in Pharmacology","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/B978-0-12-398339-8.00002-1","article-title":"The Keap1\u2013Nrf2 cell defense pathway \u2013 a promising therapeutic target?","author":"Copple","year":"2012"},{"issue":"2","key":"10.1016\/j.msard.2019.02.027_bib0003","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s00401-015-1452-x","article-title":"Cell type-specific Nrf2 expression in multiple sclerosis lesions","volume":"130","author":"Licht-Mayer","year":"2015","journal-title":"Acta Neuropathol. (Berl)"},{"issue":"1","key":"10.1016\/j.msard.2019.02.027_bib0004","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1124\/jpet.111.190132","article-title":"Fumarates promote cytoprotection of central nervous system cells against oxidative stress via the nuclear factor (erythroid-derived 2)-like 2 pathway","volume":"341","author":"Scannevin","year":"2012","journal-title":"J. Pharmacol. Exp. Ther."},{"issue":"2","key":"10.1016\/j.msard.2019.02.027_bib0005","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/toxsci\/kfp274","article-title":"The absence of the pro-antioxidant transcription factor Nrf2 exacerbates experimental autoimmune encephalomyelitis","volume":"114","author":"Johnson","year":"2010","journal-title":"Toxicol. Sci."},{"issue":"3","key":"10.1016\/j.msard.2019.02.027_bib0006","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1093\/brain\/awq386","article-title":"Fumaric acid esters exert neuroprotective effects in neuroinflammation via activation of the Nrf2 antioxidant pathway","volume":"134","author":"Linker","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.msard.2019.02.027_bib0007","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1126\/science.aan4665","article-title":"Dimethyl fumarate targets GAPDH and aerobic glycolysis to modulate immunity","volume":", 360 ,","author":"Kornberg","year":"2018","journal-title":"Science"},{"key":"10.1016\/j.msard.2019.02.027_bib0008","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/j.tifs.2017.02.002","article-title":"KEAP1 and done? Targeting the NRF2 pathway with sulforaphane","volume":"69","author":"Dinkova-Kostova","year":"2017","journal-title":"Trends Food Sci. Technol."},{"issue":"12","key":"10.1016\/j.msard.2019.02.027_bib0009","doi-asserted-by":"crossref","first-page":"3171","DOI":"10.1007\/s11095-011-0500-z","article-title":"Metabolism and tissue distribution of sulforaphane in Nrf2 knockout and wild-type mice","volume":"28","author":"Clarke","year":"2011","journal-title":"Pharm. Res."},{"issue":"12","key":"10.1016\/j.msard.2019.02.027_bib0010","doi-asserted-by":"crossref","first-page":"2347","DOI":"10.1089\/ars.2010.3731","article-title":"Pharmacological targeting of the transcription factor Nrf2 at the basal ganglia provides disease modifying therapy for experimental parkinsonism","volume":"14","author":"Jazwa","year":"2011","journal-title":"Antioxid. Redox Signal."},{"key":"10.1016\/j.msard.2019.02.027_bib0011","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.expneurol.2013.10.002","article-title":"Sulforaphane ameliorates the development of experimental autoimmune encephalomyelitis by antagonizing oxidative stress and Th17-related inflammation in mice","volume":"250","author":"Li","year":"2013","journal-title":"Exp. Neurol."},{"issue":"3","key":"10.1016\/j.msard.2019.02.027_bib0012","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/0165-5728(92)90016-E","article-title":"Induction of active and adoptive relapsing experimental autoimmune encephalomyelitis (EAE) using an encephalitogenic epitope of proteolipid protein","volume":"38","author":"McRae","year":"1992","journal-title":"J. Neuroimmunol."},{"issue":"1 Supplement","key":"10.1016\/j.msard.2019.02.027_bib0013","doi-asserted-by":"crossref","first-page":"171.6","DOI":"10.4049\/jimmunol.188.Supp.171.6","article-title":"Immunization method influences EAE relapse rate in SJL mice (171.6)","volume":"188","author":"Marusic","year":"2012","journal-title":"J. Immunol."},{"issue":"3","key":"10.1016\/j.msard.2019.02.027_bib0014","doi-asserted-by":"crossref","first-page":"30","DOI":"10.3390\/antiox5030030","article-title":"Protandim protects oligodendrocytes against an oxidative insult","volume":"5","author":"Lim","year":"2016","journal-title":"Antioxidants"},{"issue":"5","key":"10.1016\/j.msard.2019.02.027_bib0015","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1523\/JNEUROSCI.3817-03.2004","article-title":"Nuclear factor E2-related factor 2-dependent antioxidant response element activation by <em>tert<\/em>-butylhydroquinone and sulforaphane occurring preferentially in astrocytes conditions neurons against oxidative insult","volume":"24","author":"Kraft","year":"2004","journal-title":"J. Neurosci."},{"issue":"1","key":"10.1016\/j.msard.2019.02.027_bib0016","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2249.2006.03094.x","article-title":"Fumaric acid esters are effective in chronic experimental autoimmune encephalomyelitis and suppress macrophage infiltration","volume":"145","author":"Schilling","year":"2006","journal-title":"Clinic. Exp. Immunol."},{"issue":"3","key":"10.1016\/j.msard.2019.02.027_bib0017","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0120254","article-title":"Dimethyl fumarate and monoethyl fumarate exhibit differential effects on KEAP1, NRF2 activation, and glutathione depletion in vitro","volume":"10","author":"Brennan","year":"2015","journal-title":"PLoS One"},{"issue":"2","key":"10.1016\/j.msard.2019.02.027_bib0018","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1093\/toxsci\/kfu080","article-title":"Chemical tuning enhances both potency toward Nrf2 and in vitro therapeutic index of triterpenoids","volume":"140","author":"Copple","year":"2014","journal-title":"Toxicol. Sci."},{"issue":"10","key":"10.1016\/j.msard.2019.02.027_bib0019","doi-asserted-by":"crossref","first-page":"2173","DOI":"10.3390\/ijms18102173","article-title":"Nrf2-inducers counteract neurodegeneration in frataxin-silenced motor neurons: disclosing new therapeutic targets for Friedreich's ataxia","volume":"18","author":"Petrillo","year":"2017","journal-title":"Int. J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.msard.2019.02.027_bib0020","article-title":"Dimethyl fumarate for multiple sclerosis","author":"Xu","year":"2015","journal-title":"Cochrane Database Syst. Rev."},{"issue":"3","key":"10.1016\/j.msard.2019.02.027_bib0021","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1096\/fj.07-9574LSF","article-title":"Dose translation from animal to human studies revisited","volume":"22","author":"Reagan-Shaw","year":"2008","journal-title":"FASEB J."},{"issue":"2","key":"10.1016\/j.msard.2019.02.027_bib0022","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s00401-016-1631-4","article-title":"Multiple sclerosis: experimental models and reality","volume":"133","author":"Lassmann","year":"2017","journal-title":"Acta Neuropathol. (Berl)"},{"key":"10.1016\/j.msard.2019.02.027_bib0023","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1016\/j.jneuroim.2008.05.034","article-title":"An experimental model of secondary progressive multiple sclerosis that shows regional variation in gliosis, remyelination, axonal and neuronal loss","volume":"201","author":"Hampton","year":"2008","journal-title":"J. Neuroimmunol."},{"key":"10.1016\/j.msard.2019.02.027_bib0024","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1016\/j.msard.2018.05.007","article-title":"Real-life persistence and tolerability with dimethyl fumarate","volume":"24","author":"Sejbaek","year":"2018","journal-title":"Mult. Scler. Relat. Dis."},{"issue":"4","key":"10.1016\/j.msard.2019.02.027_bib0025","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1212\/WNL.0000000000002900","article-title":"PML during dimethyl fumarate treatment of multiple sclerosis: how does lymphopenia matter?","volume":"87","author":"Lehmann-Horn","year":"2016","journal-title":"Neurology"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103481930104X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S221103481930104X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,31]],"date-time":"2025-10-31T08:43:47Z","timestamp":1761900227000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S221103481930104X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":27,"alternative-id":["S221103481930104X"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2019.02.027","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"SFX-01 reduces residual disability after experimental autoimmune encephalomyelitis","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2019.02.027","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}]}}